Overview
KRAS mutations are present in more than 90% of pancreatic ductal adenocarcinomas. Our lab is at the forefront of targeting KRAS G12D — the most common substitution variant in pancreatic cancer, found in roughly 40% of patients.
First-in-class therapeutics
We led the first-in-human trial of setidegrasib (ASP3082), a first-in-class KRAS G12D targeted protein degrader, published in the New England Journal of Medicine (2026).
We also contributed to the phase 1–2 study of daraxonrasib (RMC-6236), an oral RAS(ON) multiselective inhibitor that targets GTP-bound mutant and wild-type RAS, with encouraging activity in previously treated RAS-mutated PDAC.
Genomics of KRAS
Beyond drugging KRAS, we characterise how specific KRAS mutants and mutant dosage shape clinical outcomes and biology, informing which patients should receive which RAS-directed therapy.